Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-picolinium)-12-triethylammonium-dodecane dibromide (TMPD)

Limitations in efficacy and high relapse rates of currently available smoking cessation agents reveal the need for more efficacious pharmacotherapies. One strategy is to develop subtype-selective nicotinic receptor (nAChR) antagonists that inhibit nicotine-evoked dopamine (DA) release, the primary n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dwoskin, Linda P., Joyce, B. Matthew, Zheng, Guangrong, Neugebauer, Nichole M., Manda, Vamshi K., Lockman, Paul, Papke, Roger L., Bardo, Michael T., Crooks, Peter A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2104778/
https://ncbi.nlm.nih.gov/pubmed/17727820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2007.07.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados